Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Driehaus Small Cap Growth Fund 2023 Q4 Investor Letter | Buyside Digest

Back to Fund Profile (Driehaus Small Cap Growth Fund)

Primary Source Intelligence • Q4 2023 Letter Analysis

Driehaus Small Cap Growth Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Driehaus Small Cap Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+1.11%

YTD-34.31%

Annualized+16.73%

Positioning StanceConstructive

Market CapSmallCap

GeographyUS

Digest Analysis

Quick Take

"Driehaus Small Cap Growth significantly underperformed in 2022's brutal equity market. Manager sees opportunity in historic small cap discount to large caps and maintains exposure to reshoring, infrastructure spending, and biotech themes."

Executive Summary

Driehaus Small Cap Growth Strategy underperformed in Q4 2022, gaining 1.11% net versus the Russell 2000 Growth Index's 4.13% return. For the full year, the strategy declined 34.31% versus the benchmark's 26.36% decline, marking the first calendar year underperformance in eight years during one of the worst equity market years since 2008. The manager attributes poor performance to challenging macro conditions including inflation, Fed tightening, and weak market breadth that did not reward individual company earnings as typical. Despite disappointing results, the team sees opportunity in current uncertainty. Small cap valuations have reached the second largest discount to large caps in 40 years, trading at levels consistent with past recessions. The portfolio maintains exposure to secular growth themes including reshoring trends, federal infrastructure spending programs worth over $1 trillion, and biotechnology with promising clinical trial outlooks. Key risks include persistent inflation and potential recession, while catalysts center on Fed policy normalization as inflation data improves.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

Manager demonstrates moderate-high conviction through concentrated portfolio of 109 holdings with clear top 5 positions named and sized. Specific sector allocation decisions are explained with clear rationale. Strong conviction expressed in secular themes like reshoring and infrastructure spending, though some hedging language around macro uncertainty prevents higher score.

Growth Outlook

38%

BearishBullish

Neutral (38%)

Manager acknowledges challenging market conditions with inflation, Fed tightening, recession fears, and geopolitical risks remaining top concerns. However, they express cautious optimism about inflation trajectory and see opportunity in current uncertainty, noting that bad news may be priced in and valuations are attractive.

Risk Appetite

0%

DefensiveAggressive

Defensive (0%)

Portfolio positioning appears balanced with sector rotations during the quarter - reducing consumer discretionary to underweight while increasing industrials and technology exposure. No indication of significant cash raising or aggressive deployment, suggesting neutral risk positioning.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Manager made selective sector rotations during the quarter, increasing exposure to industrials and technology while reducing consumer discretionary and healthcare. This represents modest net deployment activity rather than significant cash changes, indicating selective rebalancing rather than major capital deployment or withdrawal.

Forward Guidance

25%

CautiousExpansionary

Cautious (25%)

Manager expresses selective optimism about deployment opportunities, particularly in industrials due to reshoring and infrastructure themes, and maintains overweight to therapeutics. Language suggests willingness to add selectively rather than defensive positioning.

Language Signal

0%

BearishBullish

Bearish (0%)

Language is balanced between acknowledging significant risks (recession, inflation, Fed policy mistakes) and identifying opportunities (attractive valuations, secular themes, inflation normalization). Risk and opportunity language roughly offset each other throughout the letter.

Perceived Risk

72%

Low RiskElevated

Elevated Risk (72%)

Manager identifies multiple significant macro risks including persistent inflation, Fed policy mistakes, hard economic landing, and ongoing geopolitical tensions. Extensive discussion of recession indicators and challenging market dynamics. Risk discussion is detailed and central to the investment thesis.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager sees selective opportunities in specific sectors and themes despite challenging environment. Identifies attractive valuations in small caps generally and specific opportunities in industrials, biotechnology, and technology. Characterizes environment as offering opportunity through uncertainty rather than broad-based attractiveness.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Manager demonstrates multi-year investment horizon through focus on secular themes like reshoring and infrastructure spending that will play out over several years. Discussion of clinical trial outcomes in 2023 and long-term infrastructure programs suggests 2-4 year investment timeframe rather than near-term catalyst dependency.